MACRO Trials' Clinical Trial Model Continues to Thrive Despite COVID-19

Share Article

MACRO Trials’ Unique Capacity to Move Clinical Trials Forward Amid Coronavirus Chaos Keeps Development of Medical Technologies for Rare Diseases On Track

This pandemic has provided the opportunity to demonstrate the value of a responsive, dynamic and transparent research paradigm—one that is able to continue the highest quality research in an uncertain and rapidly changing environment,” said Jonathan Cabin, CEO.

MACRO Trials (MACRO) is shifting the paradigm for performing clinical trials through a progressive, streamlined model that has emerged particularly steadfast during the COVID-19 crisis. While traditional, non-COVID medical research has been significantly disrupted by the ongoing pandemic, with resources diverted to SARS-CoV-2 clinical care or research, MACRO’s clinical trial sites continue to thrive without interruption. With a continued emphasis on rare diseases including Graves orbitopathy (also known as Graves eye disease or thyroid eye disease), and while other clinical trial sites are significantly impaired or completely shuttered as a result of the COVID pandemic, MACRO has adapted its modular regulatory infrastructure to facilitate uninterrupted patient visits and new subject enrollment throughout this crisis.

Through the coronavirus disruption, the success of MACRO’s model has demonstrated the urgent need for a clinical trial process that simplifies the outdated academic institutional research archetype. MACRO’s workflows and protocols—prioritizing streamlined connection and communication among sponsors (pharmaceutical, biotech companies), contract research organizations (CROs), investigators and patients—allow for uninterrupted progress within the research and development pipeline that serves to help people with rare diseases (defined in the United States as diseases affecting fewer than 200,000 people nationally).

Even before COVID-19, MACRO had achieved clinical trial successes by structuring their operations to be patient-centric and providing an independent resource for principal investigators to work with pharma companies. Just recently, they were the highest enrolling site in a pivotal Phase III trial involving a biologic treatment, enabling a more expedient FDA approval and subsequent market introduction of the important drug.

“We believe that patient experience is the linchpin of successful, expedient clinical trials. So we simply make that experience the foundation of every MACRO trial,” said Jonathan Cabin, MD, chief executive officer of MACRO.

MACRO supports the clinical trial process while creating value for trial subjects, investigators, CROs and sponsors who all want a better experience in their trials, particularly when it comes to predictability, efficiency and expediency.

“This pandemic has provided the opportunity to demonstrate the value of a responsive, dynamic and transparent research paradigm—one that is able to continue the highest quality research in an uncertain and rapidly changing environment,” said Cabin, adding, “Clinical research is vital to global health security, and trial site infrastructure should be designed to thrive—not falter—during global crises.”

Built upon the values of efficiency, safety, open collaboration, disruptive technology and cost-effective best practices, MACRO optimizes the clinical trial site to safely and efficiently accelerate the clinical trial process through the requisite regulatory hurdles. This ultimately translates to a more timely availability of vital, FDA-approved treatments.

About MACRO Trials
MACRO Trials (MACRO) was founded in 2009 by physician colleagues passionate about performing high-quality research within their specialties. After establishing a record of conducting industry-sponsored and investigator-initiated trials in the fields of aesthetics, dermatology and plastic surgery, MACRO applied their unique research framework to support other principal investigators in private practice. Working closely with sponsors and contract research organizations, MACRO went on to facilitate and optimize research without the associated administrative and regulatory headaches. With a mission to change the culture of clinical research, and an eye toward a technologically adaptive research paradigm, MACRO is evolving to continue to incorporate best practices in clinical trial optimization.

Additional Information
LinkedIn (https://www.linkedin.com/company/macrotrials/)
Facebook (https://www.facebook.com/MACROtrials/)
Instagram (https://www.instagram.com/macro_trials)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daniel A. Perez, COO
MACRO Trials
+1 (310) 853-8484 Ext: 701
Email >

Ella Perez, Executive Assistant
Visit website

Media